Mary Jo Laffler
Latest From Mary Jo Laffler
Takeda's Livtencity Approved For Refractory CMV Infection In Transplant Patients
Maribavir is the first antiviral agent targeting and inhibiting the pUL97 protein kinase, as well as Takeda's second new molecular entity approved by FDA this year.
Publisher’s Spotlight: Shortlist Revealed For The 2021 Citeline Awards
From a record more than 100 entries, the finalists have been selected for 12 awards, representing the best and brightest of biopharmaceutical research.
Publisher’s Spotlight: Shortlist Revealed For The 2021 Citeline Awards
From a record more than 100 entries, the finalists have been selected for 12 awards, representing the best and brightest of biopharmaceutical research.
Flexion’s Pandemic Rebound: How Zilretta Dropped 80% But Is Still Coming Out Ahead
The knee osteoarthritis injection was hit hard by COVID-19 restrictions, at first. But CEO Mike Clayman reflected in an interview about how the pandemic experience is helping fuel further growth for Zilretta.
Novartis Broadens VISION On Radioligands
Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge.
Pandemic Perspectives: What’s The New Normal For The Business Of Biopharma?
In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry.